Adenocarcinoma of the rete testis - a rare case of testicular malignancy
Language English Country Czech Republic Media print
Document type Case Reports, Journal Article
PubMed
24739050
DOI
10.14735/amko2014136
PII: 48379
Knihovny.cz E-resources
- MeSH
- Adenocarcinoma drug therapy MeSH
- Cisplatin administration & dosage MeSH
- Granulocyte Colony-Stimulating Factor administration & dosage MeSH
- Filgrastim MeSH
- Ifosfamide administration & dosage MeSH
- Middle Aged MeSH
- Humans MeSH
- Paclitaxel administration & dosage MeSH
- Polyethylene Glycols MeSH
- Antineoplastic Combined Chemotherapy Protocols therapeutic use MeSH
- Recombinant Proteins administration & dosage MeSH
- Rete Testis * MeSH
- Testicular Neoplasms drug therapy MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Publication type
- Journal Article MeSH
- Case Reports MeSH
- Names of Substances
- Cisplatin MeSH
- Granulocyte Colony-Stimulating Factor MeSH
- Filgrastim MeSH
- Ifosfamide MeSH
- Paclitaxel MeSH
- pegfilgrastim MeSH Browser
- Polyethylene Glycols MeSH
- Recombinant Proteins MeSH
BACKGROUND: Adenocarcinoma of rete testis is an extremely rare dia-gnosis described in around 70 patients worldwide. The prognosis of the disease in metastatic stage is very poor and there is no standard systemic treatment available. CASE: Herein we present a unique case report of a 47-year- old man with metastatic adenocarcinoma of rete testis who achieved substantial disease response after four cycles of paclitaxel, ifosfamide and cisplatin. The chemotherapy was administered in five -day regimen, which comprised 250 mg/ m2 of paclitaxel on day one, 20 mg/ m2 of cisplatin on day one to five and 1,2 g/ m2 of ifosfamide on day one to five, in a three-week interval. The patient received prophylactic pegfilgrastim after each cycle of TIP. The treatment was well tolerated - without any significant toxicity. RESULT: Patient achieved a partial 14- month remission. CONCLUSION: On basis of this experience we suggest that paclitaxel, ifosfamide and cisplatin might be adopted as novel agents in treatment of rete testis adenocarcinoma.
References provided by Crossref.org